Anterior Uveitis Market Report 2026

Anterior Uveitis Market Overview

• Anterior Uveitis market size has reached to $0.57 billion in 2025 • Expected to grow to $0.98 billion in 2030 at a compound annual growth rate (CAGR) of 11.2% • Growth Driver: Impact Of Autoimmune Disease Surge On Inflammatory Eye Conditions • Market Trend: Advancements In Treatment Approaches For Non-Infectious Uveitis • North America was the largest region in 2025.

What Is Covered Under Anterior Uveitis Market?

Anterior uveitis refers to a condition that causes an inflammation of the eye's middle layer, which includes the iris (the colored part of the eye) and the ciliary body, the adjacent tissue. Anterior uveitis can occur due to eye trauma, such as a direct blow or the presence of a foreign object in the eye. It can also be linked to general health issues such as rheumatoid arthritis, syphilis, tuberculosis, sarcoidosis, or viral infections (herpes simplex, herpes zoster, cytomegalovirus), or it can be idiopathic, with no identifiable underlying cause. The main treatment types for anterior uveitis are pharmacological therapies, surgical interventions, and biologic treatments. Pharmacological therapies involve the administration of medications to alleviate inflammation and control symptoms. Diagnosis methods include clinical evaluation, diagnostic imaging, and biomarker testing. The condition can have infectious or non-infectious causes and can be used in hospitals and clinics, and ambulatory surgical centers.

What Is The Anterior Uveitis Market Growth Forecast?

The anterior uveitis market size is expected to see rapid growth in the next few years. It will grow to $0.98 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to rising demand for biologic eye therapies, increasing integration of precision diagnostics, expansion of advanced ophthalmic drug pipelines, growing focus on vision preservation, increasing investment in inflammatory eye disease research. Major trends in the forecast period include increasing adoption of biologic therapies, rising use of advanced diagnostic biomarkers, growing preference for targeted immunosuppressive treatments, expansion of outpatient ophthalmic care, enhanced focus on early disease detection.

Global Anterior Uveitis Market Segmentation

1) By Treatment Type: Pharmacological Treatments, Surgical Treatments, Biologic Therapy 2) By Diagnosis Method: Clinical Diagnosis, Diagnostic Imaging, Biomarkers 3) By Cause: Infectious, Non-Infectious 4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers Subsegments: 1) By Pharmacological Treatments: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Immunosuppressive Drugs 2) By Surgical Treatments: Cataract Surgery, Glaucoma Surgery, Vitrectomy 3) By Biologic Therapy: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, Monoclonal Antibodies

What Is The Driver Of The Anterior Uveitis Market?

The rising prevalence of autoimmune diseases is expected to drive the growth of the anterior uveitis market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells and tissues, treating them as foreign threats. This abnormal response leads to inflammation and damage in various organs and systems. The rise in autoimmune diseases is linked to genetic predispositions, environmental factors, lifestyle changes, and increased awareness, leading to better diagnosis. Anterior uveitis is a common manifestation in autoimmune diseases, causing inflammation in the eye's anterior segment, often associated with conditions such as rheumatoid arthritis and ankylosing spondylitis. For instance, in February 2024, according to Arthritis Australia, an Australia-based charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions, by 2025, approximately 562,378 Australians are living with rheumatoid arthritis (RA), accounting for 14% of the total arthritis population. Therefore, the rising prevalence of autoimmune diseases is driving the growth of the anterior uveitis industry.

Key Players In The Global Anterior Uveitis Market

Major companies operating in the anterior uveitis market are AbbVie Inc, Novartis AG, Bausch Health Companies Inc, EyePoint Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Clearside Biomedical Inc, Eyegate Pharmaceuticals Inc, Horizon Therapeutics Plc, Mylan NV, Sun Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, Pfizer Inc, Amgen Inc, Sanofi, Galapagos NV, Tarsier Pharma Ltd, TopiVert Ltd, Ocular Therapeutix Inc, Ophthotech Corporation, Aciont Inc, Sirion Therapeutics Inc, Aldeyra Therapeutics Inc, Kiora Pharmaceuticals Inc, UCB SA, ANI Pharmaceuticals Inc, Priovant Therapeutics, Roivant Sciences Inc, Active Biotech

Global Anterior Uveitis Market Trends and Insights

Major companies operating in the anterior uveitis market are focusing on developing advanced drug formulations, such as eye drops, to improve patient compliance, enhance drug delivery, and reduce inflammation with fewer side effects. Eye drops are frequently used in the treatment of anterior uveitis to manage inflammation, alleviate pain, and prevent potential complications. For instance, in January 2024, Tarsier Pharma Ltd., an Israel-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the clinical trial protocol and statistical analysis plan of the Tarsier-04 Phase 3 trial. This trial aims to evaluate the effectiveness of TRS01 eye drops in treating non-infectious uveitis, including uveitic glaucoma. The Tarsier-04 trial is a multicenter, randomized, double-masked, active-controlled study enrolling up to 300 patients in the U.S., with the goal of demonstrating TRS01’s safety and efficacy, particularly in controlling inflammation without increasing glaucoma risk.

What Are Latest Mergers And Acquisitions In The Anterior Uveitis Market?

In January 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Oxular Limited for an undisclosed amount. This acquisition provides Regeneron with an advanced delivery device for ocular gene therapies, accelerating its path to clinical readiness. By utilizing Oxular’s proprietary technologies, Regeneron is poised to advance therapeutic precision and innovation in eye care. Oxular Limited is a UK-based biotech company that specializes in developing drug and device treatments for retinal disorders, including anterior uveitis disorder.

Regional Outlook

North America was the largest region in the anterior uveitis market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anterior Uveitis Market?

The anterior uveitis market consists of revenues earned by entities by provide services such as slit-lamp examinations, optical coherence tomography (OCT), ultrasound biomicroscopy, corticosteroid administration, and glaucoma management. The market value includes the value of related goods sold by the service provider or included within the service offering. The anterior uveitis market also includes sales of corticosteroids (topical and systemic), non-steroidal anti-inflammatory drugs (NSAIDS), and immunosuppressive drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anterior Uveitis Market Report 2026?

The anterior uveitis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anterior uveitis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.